Clinical Feasibility of Disease Managing Mobile App for Hyperthyroidism
Clinical Feasibility of Disease-managing Mobile Application in the Patients With Hyperthyroidism
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Recruiting
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who have been newly diagnosed or are currently undergoing treatment for thyrotoxicosis at Bundang Seoul National University Hospital.
- Subjects must be able to use the smartphone app required for the use of wearable devices and their integration.
Exclusion Criteria:
- Subjects who have constraints on normal activity due to diseases other than thyroid dysfunction.
- Subjects who are currently taking medication that affects heart rate.
- Subjects with heart conditions such as arrhythmia that affect heart rate.
- Subjects who cannot undergo antithyroid drug treatment and require surgery or radioactive iodine therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: app user group
The participants in this group start using wearable devices to monitor their heart rate and a mobile app to assist with the management of hyperthyroidism after being diagnosed and beginning treatment with anti-thyroid medication.
|
Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
|
|
No Intervention: non-user group
The participants in this group begin treatment with anti-thyroid medication after being diagnosed with thyrotoxicosis, but they do not use the wearable devices or mobile app used in this study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scores of quality of life assessed by SF-36 survey
Time Frame: baseline (at enrollment)
|
Scores of quality of life assessed by SF-36 survey
|
baseline (at enrollment)
|
|
Scores of quality of life assessed by SF-36 survey
Time Frame: 6 weeks after baseline
|
Scores of quality of life assessed by SF-36 survey
|
6 weeks after baseline
|
|
Scores of quality of life assessed by SF-36 survey
Time Frame: 10 weeks after baseline
|
Scores of quality of life assessed by SF-36 survey
|
10 weeks after baseline
|
|
Scores of quality of life assessed by SF-36 survey
Time Frame: 14 weeks after baseline
|
Scores of quality of life assessed by SF-36 survey
|
14 weeks after baseline
|
|
antithyroidal drug compliance
Time Frame: 6 weeks after baseline
|
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
|
6 weeks after baseline
|
|
antithyroidal drug compliance
Time Frame: 10 weeks after baseline
|
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
|
10 weeks after baseline
|
|
antithyroidal drug compliance
Time Frame: 14 weeks after baseline
|
Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication.
|
14 weeks after baseline
|
|
Knowledge about hyperthyroidism
Time Frame: 14 weeks after baseline
|
A score measured through a test designed to assess the knowledge level about Graves' disease
|
14 weeks after baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
free T4
Time Frame: baseline
|
serum free T4 concentration
|
baseline
|
|
free T4
Time Frame: 6 weeks after baseline
|
serum free T4 concentration
|
6 weeks after baseline
|
|
free T4
Time Frame: 10 weeks after baseline
|
serum free T4 concentration
|
10 weeks after baseline
|
|
free T4
Time Frame: 14 weeks after baseline
|
serum free T4 concentration
|
14 weeks after baseline
|
|
free T3
Time Frame: baseline
|
serum free T3 concentration
|
baseline
|
|
free T3
Time Frame: 6 weeks after baseline
|
serum free T3 concentration
|
6 weeks after baseline
|
|
free T3
Time Frame: 10 weeks after baseline
|
serum free T3 concentration
|
10 weeks after baseline
|
|
free T3
Time Frame: 14 weeks after baseline
|
serum free T3 concentration
|
14 weeks after baseline
|
|
TSH
Time Frame: baseline
|
serum free TSH concentration
|
baseline
|
|
TSH
Time Frame: 6 weeks after baseline
|
serum free TSH concentration
|
6 weeks after baseline
|
|
TSH
Time Frame: 10 weeks after baseline
|
serum free TSH concentration
|
10 weeks after baseline
|
|
TSH
Time Frame: 14 weeks after baseline
|
serum free TSH concentration
|
14 weeks after baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B-2201-735-304
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.